Bristol-Myers Squibb Co's last attempt to revive a case, which alleges that Mylan Laboratories Ltd has breached an agreement to distribute an AIDS drug in developing countries, has failed. A federal judge in Manhattan has rejected the attempt.

US District Judge Paul Engelmayer said the case has already been amended, dismissed, reinstated on appeal and dismissed again and reviving it would not make sense. Meanwhile, Bristol-Myers continues to work on its development of drugs.

It affirmed on Tuesday that federal regulators will help speed development of one of its experimental HIV drugs. The company's drug BMS-663068 has been termed as a breakthrough treatment by the Food and Drug Administration.

Therefore, Bristol-Myers will have additional meetings with the FDA and earlier communication with scientists. The drug is meant to be used in combination with other antiretroviral drugs in adults who have developed resistance to many other types of HIV treatment. Currently, the company has been carrying out late stage trials of the drug.

The drug has been designed in a way that it will stick to HIV cells and will stop them from binding with a type of white blood cell. The company already sells many HIV drugs, including Reyataz and Evotaz. The former is one of Bristol-Myers top products.

In June, the company announced of ending its early-stage research in HIV and hepatitis B, so that it can focus on other fields.